Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy
about
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.Antiangiogenic therapy for glioblastoma: current status and future prospects.Retinal upregulation of inflammatory and proangiogenic markers in a model of neonatal diabetic rats fed on a high-fat-diet.Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker.A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.Anti-VEGF/VEGFR therapy for cancer: reassessing the target.Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targetsIntegrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy.Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition.Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.Controlling escape from angiogenesis inhibitors.Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.Resistance to antiangiogenic therapy.Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.Future options of anti-angiogenic cancer therapy.Soluble vascular endothelial-cadherin and auto-antibodies to human vascular endothelial-cadherin in human diseases: Two new biomarkers of endothelial dysfunction.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Resistance to metronomic chemotherapy and ways to overcome it.Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.Thermal tomography for monitoring tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancerVasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma.Molecular Mechanisms of Preeclampsia.
P2860
Q27000351-25FCCCD5-11CE-42A2-A5B7-929ABBE9C572Q34523319-E63B534B-E12C-417F-BDDF-1B7F963B88F3Q34669369-5FD5069F-C7BB-4401-AE36-D791DCBD8A49Q35072480-D63D5FAE-237A-427B-9134-1B884C97288CQ35101358-4E948D5F-0034-47F3-ACB5-AF91D2E364A2Q35475535-84871591-35F7-48CD-91DD-38A5B5192E1CQ35547649-8416F102-850D-42B9-8585-4BCF1E1298BCQ35910772-C33E187C-F083-44E5-8476-0AC5959FC353Q36357152-CD3ED02E-0791-41EB-9635-2EC01315FC45Q36436763-B3219D16-A120-4263-9B1F-B72E6B2B944DQ36468606-2B303C56-A95B-4FC7-8A13-4053224E8D1AQ36713499-02F5FD54-8CA8-4F44-B959-BEA202CC30D6Q36828050-2EBB94A8-8DF3-4490-BD08-8A347B4AB1A6Q37185773-8B07A646-3D93-4887-8F2C-8A0927BE09ACQ37236229-BB52EA4E-A5FD-484F-A853-7ED0E6AD2EE1Q37558971-FB269A45-8FB7-4009-8D2F-727BADBA136FQ37672654-314E114F-2E60-4854-9C49-6EF72B126DA5Q38046514-891B90B9-B035-4F93-91E7-AB4417D63F55Q38197943-DD3D2D31-EB40-4D2F-ADA1-5722F4FE3509Q38317180-B5103F91-5CF6-479F-9415-9CACC53DA32FQ38438425-72EDACC0-6E3D-4F07-A499-404D6BA63D7EQ38541002-1E9118DB-2358-4626-8835-89E4EB865471Q39022941-FE6C4810-479B-4393-B471-F06FBE7EE88CQ40448516-EEC92D95-7899-4676-996A-5B8A42D45D9CQ41954266-5D67378B-3374-4DFC-ADBD-949F8420DFFEQ42141918-9AE51BBA-388E-4BF4-87FF-15299F0E95D7Q47733432-0064CD18-F6C9-465A-9018-B2D6EB5E11E3Q54901493-0CEDD8F5-8954-4DBE-9FCA-A1427F88EB77
P2860
Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Tumor-surrogate blood vessel s ...... ptibility to anti-VEGF therapy
@ast
Tumor-surrogate blood vessel s ...... ptibility to anti-VEGF therapy
@en
type
label
Tumor-surrogate blood vessel s ...... ptibility to anti-VEGF therapy
@ast
Tumor-surrogate blood vessel s ...... ptibility to anti-VEGF therapy
@en
prefLabel
Tumor-surrogate blood vessel s ...... ptibility to anti-VEGF therapy
@ast
Tumor-surrogate blood vessel s ...... ptibility to anti-VEGF therapy
@en
P2093
P2860
P1433
P1476
Tumor-surrogate blood vessel s ...... ptibility to anti-VEGF therapy
@en
P2093
Basel Sitohy
Harold F Dvorak
Janice A Nagy
Shou-Ching Shih Jaminet
P2860
P304
P356
10.1158/0008-5472.CAN-11-1693
P407
P577
2011-09-21T00:00:00Z